1. Home
  2. PGY vs MESO Comparison

PGY vs MESO Comparison

Compare PGY & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$21.85

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$19.50

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
MESO
Founded
2016
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PGY
MESO
Price
$21.85
$19.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$39.86
$24.00
AVG Volume (30 Days)
2.5M
247.0K
Earning Date
02-12-2026
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,245,946,000.00
$17,198,000.00
Revenue This Year
$28.75
$576.59
Revenue Next Year
$17.23
$41.15
P/E Ratio
N/A
N/A
Revenue Growth
28.33
191.39
52 Week Low
$8.27
$9.61
52 Week High
$44.99
$22.00

Technical Indicators

Market Signals
Indicator
PGY
MESO
Relative Strength Index (RSI) 40.60 65.75
Support Level $22.72 $19.00
Resistance Level $24.06 $19.90
Average True Range (ATR) 1.31 0.55
MACD 0.01 0.09
Stochastic Oscillator 16.63 85.20

Price Performance

Historical Comparison
PGY
MESO

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: